Nearly one in three hospital deaths is linked to sepsis—a fast-moving condition where every hour without targeted treatment decreases survival by 8%. Within 12 hours of infection, patients face a risk of septic shock, carrying a mortality rate up to 50%. Meanwhile, traditional pathogen identification diagnostics take 12 to 48 hours, forcing clinicians to make critical treatment decisions without knowing the underlying bacteria.
Diagnostic Ventures was born to eliminate this delay. Originating in 2017 through research led by Dr. William Pitt at Brigham Young University and supported by a $5.2M NIH grant, our team tackled bioengineering’s ultimate needle-in-a-haystack problem: isolating 5 to 10 bacterial cells from billions of host cells. Rather than relying on culture bottlenecks, we engineered a proprietary centrifuge platform that isolates plasma in under four minutes.
Today, operating at BYU in partnership with Dr. Richard Robison’s BSL-3 facilities, we are combining our centrifuge technology with downstream bacterial isolation, Raman spectroscopy, and machine learning to reach 98–99% clinical sensitivity. Additionally, we are working with a partner institution to develop a rapid AST platform, targeting results in under 30 minutes. Backed by exclusive worldwide patent rights and a team determined to execute on our vision, Diagnostic Ventures is positioned to help save many sepsis patients' lives.
Solving healthcare's deadliest diagnostic challenges by pioneering advanced, rapid testing systems that eliminate the wait for effective patient treatment.
Built on a foundation of rigorous academic discovery and proven clinical execution, our team brings centuries of collective expertise to the frontline of medicine. We have turned our focus toward pioneering the advanced rapid diagnostics necessary to eradicate sepsis and redefine acute patient care.
